Actinium-225

EN Texto em inglês Ainda não há artigo no teu idioma: trecho em inglês.

Actinium-225 (Ac, Ac-225) is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life near 10 days, and is an intermediate decay product in the neptunium series (the decay chain starting at Np). Except for minuscule quantities arising from this decay chain in nature, Ac is entirely synthetic. The decay properties of actinium-225 (emitting four alpha particles within about an hour) are favorable for usage in targeted alpha therapy (TAT); clinical trials have demonstrated the applicability of radiopharmaceuticals containing Ac to treat various types of cancer. However, the scarcity of this isotope resulting from its necessary synthesis in cyclotrons limits its potential applications. Another such isotope, bismuth-213, is produced necessarily (given its short half-life) from the decay of actinium-225 in a generator and immediate use; it gives only the last of the four alpha particles, requiring a larger amount of actinium, but may be preferred if available. Actinium-225 decays exclusively by alpha emission. It is part of the neptunium series, for it arises as a decay product of neptunium-237 and its daughters such as uranium-233 and thorium-229. It is the last nuclide in the chain with a half-life over a day until the penultimate product, bismuth-209 (half-life 2.01×10 years). The final decay product of Ac is stable Tl.